1. Cu-64-Anti-CEA M5A as a Novel Theranostics PET Imaging Agent Pre and Post Neoadjuvant Radiotherapy in Advanced Rectal Cancer.
- Author
-
Wong, J.Y.C., Chen, Y.J., Yamauchi, D.M., Chen, H.K., McGee, H.M., Lee, P., Melstrom, K., Lai, L., Fakih, M., Poku, E., Frankel, P., Wu, A., Yazaki, P., and Shively, J.E.
- Subjects
- *
POSITRON emission tomography , *CANCER patients , *MAGNETIC resonance imaging , *NEOADJUVANT chemotherapy , *COMPUTED tomography , *RECTAL cancer , *ABDOMINOPERINEAL resection - Abstract
Prior studies have demonstrated that radiolabeled anti-carcinoembryonic antigen (CEA) monoclonal antibody (M5A) can target CEA-expressing cancers. This ongoing pilot study (NCT05245786) evaluates the ability of Cu-64-DOTA-M5A PET imaging to define disease extent before and after neoadjuvant radiotherapy in patients with locally advanced rectal cancer. Patients with biopsy proven cT3-4, N0 or N+ rectal cancer who were scheduled for neoadjuvant chemoradiation prior to TME or total neoadjuvant therapy underwent PET imaging with Cu-64-M5A within 4 weeks prior to start of neoadjuvant RT and 6-8 weeks after end of all neoadjuvant therapy and prior to planned surgery. Cu-64-M5A PET scans were read by the same nuclear medicine physician. A regional analysis (primary, pelvic nodes, and extra-pelvic) later compared CEA scans to standard of care (SOC) CT and MRI imaging, FDG PET if available, biopsies and surgical findings. Nine patients have been imaged to date with Cu-64-M5A PET (ages 46-70 years old). CEA PET imaging prior to RT identified the primary tumor in all 9 patients. For disease involving pelvic nodes, CEA PET imaging was in concordance with SOC imaging in 6 of 9 patients. In 5 patients CEA scans identified suspicious lesions outside the pelvis, which in 2 patients were confirmed by SOC imaging and biopsy (lung metastases; and a single liver metastasis), while in 3 patients PET avid nodes detected (para-aortic, left supraclavicular, mediastinal, porta hepatis, and portacaval) were outside the regions imaged as part of SOC. 4 of 9 patients to date have also been imaged post RT and prior to surgery. 2 patients had radiologic complete response (CR) on CEA scans which correlated with pathologic CR at surgery and with clinical CR on follow-up sigmoidoscopy. Two patients had positive scans; 1 patient at the primary site confirmed as residual disease at surgery; and 1 patient at the primary site, in mediastinal, para-aortic, and pelvic lymph nodes, and a new focus near the hepatic surface with biopsy confirmation of disease at the primary site and liver. Results demonstrate that Cu-64-M5A anti-CEA M5A PET imaging in patients with advanced rectal cancer shows promise in identifying known sites of disease at the primary site and regional lymph nodes, as well as identifying extra pelvic sites of disease. In addition, it shows promise for assessing response to neoadjuvant therapy. Cu-64-M5A imaging warrants further evaluation as a way to complement SOC imaging at initial staging, to select patients for local regional therapy and to select patients for non-operative management after neoadjuvant therapy. Given its targeting capabilities, M5A is also being evaluated radiolabeled with Ac-225 as a therapeutic radiopharmaceutical (NCT05204147) and as an anti-CEA-IL2 immunotherapy fusion agent (NCT06130826) in phase 1 trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF